Broad Institute

Broad Institute
Name	Broad Institute
Established	2004
Type	Biomedical and genomic research
Headquarters	Cambridge, Massachusetts
Key people	Eric Lander, Todd Golub, David Altshuler
Affiliations	Massachusetts Institute of Technology, Harvard University, Harvard-affiliated hospitals

Broad Institute is a biomedical and genomic research center located in Cambridge, Massachusetts. It was founded in 2004 as a collaborative partnership between the Massachusetts Institute of Technology, Harvard University, and the Harvard-affiliated hospitals. The institute is dedicated to advancing the understanding and treatment of disease through large-scale, interdisciplinary research in genomics and biology.

History and founding

The institute was formally launched in 2004 following a transformative gift from philanthropists Eli and Edythe Broad. This founding built upon the pioneering work of the Whitehead Institute/MIT Center for Genome Research, which had played a central role in the Human Genome Project. Key scientific leaders, including Eric Lander, were instrumental in its creation, envisioning a new model for collaborative science. The establishment was also supported by significant commitments from Harvard University and the Massachusetts Institute of Technology, solidifying its unique academic partnership.

Research programs and scientific focus

Core research is organized into scientific programs that tackle fundamental biological questions and human diseases. Major areas include the Cancer Program, the Psychiatric Disorders initiative, and the Infectious Disease and Microbiome Program. A defining focus is on developing and applying tools for functional genomics, such as CRISPR-based screening, to understand gene function. The Metabolic Disease program and the Cardiovascular Disease initiative further exemplify its disease-oriented approach, often leveraging large-scale genetic data from projects like the UK Biobank.

Organizational structure and leadership

The institute operates as a 501(c)(3) nonprofit organization. It is governed by a board chaired by Harvard University leadership, with representation from MIT and the Harvard-affiliated hospitals. The founding director was Eric Lander, who also served as a co-chair of the President's Council of Advisors on Science and Technology. Current leadership includes director Todd Golub and chief scientific officer David Altshuler. The structure is designed to foster collaboration across traditional academic boundaries, involving faculty from MIT, Harvard Medical School, and hospitals like Massachusetts General Hospital.

Key scientific contributions and discoveries

Scientists have made landmark contributions to the creation of foundational genomic resources, including the ENCODE Project and the 1000 Genomes Project. Pioneering work in CRISPR technology, led by researchers like Feng Zhang, has revolutionized genetic engineering. The institute's teams have identified numerous genetic risk factors for diseases such as schizophrenia, type 2 diabetes, and autism spectrum disorder through large genome-wide association studies. Other major advances include the development of the Cancer Cell Line Encyclopedia and pivotal discoveries in the genetics of inflammatory bowel disease.

Facilities and technological platforms

The main campus is located at 415 Main Street in Cambridge, Massachusetts, with additional space in the neighboring Kendall Square innovation district. It houses state-of-the-art, centralized scientific platforms that provide resources to the global research community. These include the Genome Sequencing Platform, the Proteomics Platform, and the Genetic Perturbation Platform for CRISPR screening. The Metabolomics Platform and the Bioinformatics and Data Science core support the analysis of massive datasets, enabling large-scale experiments that would be infeasible in individual laboratories.

Collaborations and partnerships

Collaboration is central to its mission, extending well beyond its founding partners. It is a key member of the NIH-funded Psychiatric Genomics Consortium and the International Cancer Genome Consortium. Major partnerships with pharmaceutical companies like Novartis and Pfizer aim to translate discoveries into therapies. The institute also leads or participates in global public health initiatives, such as efforts with the World Health Organization against pathogens like SARS-CoV-2 and Ebola virus. These alliances with entities like the Dana-Farber Cancer Institute and the Howard Hughes Medical Institute amplify its scientific impact.

Category:Research institutes in Massachusetts Category:Genomics organizations Category:Harvard University Category:Massachusetts Institute of Technology